Everest Medicines, a New York biopharma that develops novel drugs for Greater China and Asia, has dosed the first patient in a China Phase III trial of etrasimod, a novel treatment for ulcerative colitis. In 2017, Everest in-licensed greater China rights to etrasimod from Arena Pharma of San Diego in a $224 million two-drug agreement. Everest was backed with $50 million in initial financing led by China's C-Bridge Capital and set up as a C-Bridge incubator platform for bringing novel drugs to China. More details.... Stock Symbol: (NSDQ: ARNA) Share this with colleagues: // //